Autolus Therapeutics plc 6A3A.F Stock
Autolus Therapeutics plc Price Chart
Autolus Therapeutics plc 6A3A.F Financial and Trading Overview
| Autolus Therapeutics plc stock price | 3.66 EUR |
| Previous Close | 2.62 EUR |
| Open | 2.54 EUR |
| Bid | 2.54 EUR x 0 |
| Ask | 2.62 EUR x 0 |
| Day's Range | 2.54 - 2.54 EUR |
| 52 Week Range | 1.47 - 3.64 EUR |
| Volume | 30 EUR |
| Avg. Volume | 159 EUR |
| Market Cap | 449.46M EUR |
| Beta (5Y Monthly) | 1.548476 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.11 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.61 EUR |
6A3A.F Valuation Measures
| Enterprise Value | 137.74M EUR |
| Trailing P/E | N/A |
| Forward P/E | -1.3804348 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 60.040157 |
| Price/Book (mrq) | 1.6472113 |
| Enterprise Value/Revenue | 18.4 |
| Enterprise Value/EBITDA | -0.872 |
Trading Information
Autolus Therapeutics plc Stock Price History
| Beta (5Y Monthly) | 1.548476 |
| 52-Week Change | 40.10% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.64 EUR |
| 52 Week Low | 1.47 EUR |
| 50-Day Moving Average | 2.04 EUR |
| 200-Day Moving Average | 2.18 EUR |
6A3A.F Share Statistics
| Avg. Volume (3 month) | 159 EUR |
| Avg. Daily Volume (10-Days) | 3 EUR |
| Shares Outstanding | 173.08M |
| Float | 67.66M |
| Short Ratio | N/A |
| % Held by Insiders | 8.44% |
| % Held by Institutions | 76.89% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2205.22% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.044% |
| Return on Equity (ttm) | -56.34% |
Income Statement
| Revenue (ttm) | 7.49M EUR |
| Revenue Per Share (ttm) | 0.07 EUR |
| Quarterly Revenue Growth (yoy) | 678.30% |
| Gross Profit (ttm) | -130860000 EUR |
| EBITDA | -157894000 EUR |
| Net Income Avi to Common (ttm) | -151588000 EUR |
| Diluted EPS (ttm) | -1.27 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 343.03M EUR |
| Total Cash Per Share (mrq) | 1.98 EUR |
| Total Debt (mrq) | 27.32M EUR |
| Total Debt/Equity (mrq) | 10.23 EUR |
| Current Ratio (mrq) | 9.937 |
| Book Value Per Share (mrq) | 1.542 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -119697000 EUR |
| Levered Free Cash Flow (ttm) | -104842376 EUR |
Profile of Autolus Therapeutics plc
| Country | Germany |
| State | N/A |
| City | London |
| Address | The MediaWorks |
| ZIP | W12 7FP |
| Phone | 44 20 3829 6230 |
| Website | https://www.autolus.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 399 |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Q&A For Autolus Therapeutics plc Stock
What is a current 6A3A.F stock price?
Autolus Therapeutics plc 6A3A.F stock price today per share is 3.66 EUR.
How to purchase Autolus Therapeutics plc stock?
You can buy 6A3A.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Autolus Therapeutics plc?
The stock symbol or ticker of Autolus Therapeutics plc is 6A3A.F.
Which industry does the Autolus Therapeutics plc company belong to?
The Autolus Therapeutics plc industry is Biotechnology.
How many shares does Autolus Therapeutics plc have in circulation?
The max supply of Autolus Therapeutics plc shares is 266.04M.
What is Autolus Therapeutics plc Price to Earnings Ratio (PE Ratio)?
Autolus Therapeutics plc PE Ratio is now.
What was Autolus Therapeutics plc earnings per share over the trailing 12 months (TTM)?
Autolus Therapeutics plc EPS is -1.11 EUR over the trailing 12 months.
Which sector does the Autolus Therapeutics plc company belong to?
The Autolus Therapeutics plc sector is Healthcare.